By Editor , 17 September 2026
First Mining Gold Added to VanEck Junior Gold Miners GDXJ Index

Vancouver – September 17, 2026 -- First Mining Gold Corp. (TSX: FF; OTCQX: FFMGF; FRANKFURT: FMG) will join the MVIS Global Junior Gold Miners Index (MVGDXJ), the benchmark tracked by the VanEck Junior Gold Miners ETF (GDXJ), effective at the close of trading on September 18, 2026.

By Editor , 17 September 2026
Hyperscale Data Sets $750M Floor Valuation for Michigan AI Campus

Las Vegas – September 17, 2026 -- Hyperscale Data, Inc. (NYSE American: GPUS) has set $750 million as the minimum valuation at which it would seriously consider selling its Michigan AI data center campus, with management estimating the asset could fetch as much as $1.25 billion.

By Editor , 17 September 2026
Solidion Technology Authorizes $1 Million Stock Buyback Program

Dallas – – September 17, 2026 -- Solidion Technology, Inc. (NASDAQ: STI) has authorized a stock buyback program worth up to $1.0 million, effective September 13, 2026.

Board sets buyback ceiling at $1.0 million through March 2028

The repurchase authorization will remain active until the full $1.0 million is spent, until March 14, 2028, or until the Board terminates it, whichever comes first. Open-market repurchases will follow federal securities laws, Nasdaq requirements and applicable state law.

By Editor , 17 September 2026

Stockholm – September 16, 2026 -- Telefonaktiebolaget LM Ericsson repurchased Class B shares on Nasdaq Stockholm between September 7 and September 11, 2026, pushing its total treasury stock holding to 107,518,663 Class B shares.

Ericsson executes buyback under a SEK 15 billion program launched in April 2026

The repurchases form part of a share buyback program of up to SEK 15,000,000,000 that Ericsson announced on April 16, 2026. The program runs from April 23, 2026, through March 31, 2027, at the latest.

By Editor , 17 September 2026

Dublin – September 16, 2026 -- Davion Healthcare Plc has secured admission of a £30 million senior secured bond to trading on the Vienna MTF, operated by Wiener Börse AG, giving the Irish healthcare group a dedicated capital pool to fund acquisitions.

Bond carries 10.5% fixed coupon over five-year term

The bond, issued through financing subsidiary Davion Healthcare Finance Ltd, commenced in August 2026 and carries a fixed annual coupon of 10.5%. It trades under ISIN GB00BTH2SB89, with a denomination of £100,000 per unit.

By Editor , 17 September 2026
Sophia Space Secures $300M SLI Lease Deal for Orbital Compute Fleet

Pasadena – September 16, 2026 -- Sophia Space has entered a $300 million financing framework with aerospace leasing specialist SLI to fund a 10-satellite edge computing constellation, applying asset-leasing models long used in aviation and energy to orbital infrastructure for the first time.

By Editor , 17 September 2026
RYBREVANT Combo Extends Survival to 34.3 Months in Lung Cancer Trial

Seoul – September 16, 2026 -- Johnson & Johnson reported that its RYBREVANT (amivantamab-vmjw) plus chemotherapy combination extended median overall survival to 34.3 months in patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer, compared with 27.9 months for chemotherapy alone, according to final data from the Phase 3 PAPILLON study.

By Editor , 17 September 2026
Franco-Nevada Adds A$200M Royalty, Equity Deal for Bullabulling Gold

Toronto – September 16, 2026 -- Franco-Nevada Corporation has agreed to a A$200 million (approximately $144 million) follow-on financing package with Minerals 260 Limited to advance the Bullabulling Gold Project in Western Australia, lifting its total backing of the project to an aggregate A$420 million (approximately $300 million).

The package comprises a A$170 million (approximately $122 million) gross royalty acquisition and a A$30 million (approximately $22 million) equity subscription as lead order in a future Minerals 260 capital raise.

By Editor , 17 September 2026

Hong Kong – September 16, 2026 -- Akeso, Inc. (9926.HK) reported that its bispecific antibody ivonescimab reduced the risk of death by 27% compared with Merck's pembrolizumab in a Phase III trial of PD-L1-positive non-small cell lung cancer (NSCLC), with results presented as a Late-Breaking Abstract at the 2026 World Conference on Lung Cancer (WCLC).